Skip to main content
OpenTrials
Completed

NCT Number: NCT00262483

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis C Blood-Borne Infections Communicable Diseases Digestive System Diseases Flaviviridae Infections Hepatitis Hepatitis, Viral, Human Infections Liver Diseases RNA Virus Infections Virus Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Call for information, Santurce, Puerto Rico

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infected with hepatitis C virus

Exclusion criteria

  • Contraindications to peginterferon or ribavirin therapy.

Treatment and study plan

VX-950

Drug

Ribavirin

Drug

Peginterferon alfa-2a

Drug

Primary outcomes

  1. Safety of triple combination therapy.

    Time frame: retrospective and prospective

Secondary outcomes

  1. Pharmacokinetics of VX-950, peginterferon alfa-2a and ribavirin.

    Time frame: retrospective and prospective

  2. Plasma HCV RNA levels

    Time frame: retrospective and prospective

Sponsors and collaborators

Lead sponsor

Vertex Pharmaceuticals Incorporated

Industry

Registry information

Official study title

A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C

Important dates

Study start
2005
Study completion
2006
First posted
Dec 6, 2005
Registry last updated
Dec 21, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.